AU2004243542B2 - Method and article for treatment of inflammatory disease - Google Patents
Method and article for treatment of inflammatory disease Download PDFInfo
- Publication number
- AU2004243542B2 AU2004243542B2 AU2004243542A AU2004243542A AU2004243542B2 AU 2004243542 B2 AU2004243542 B2 AU 2004243542B2 AU 2004243542 A AU2004243542 A AU 2004243542A AU 2004243542 A AU2004243542 A AU 2004243542A AU 2004243542 B2 AU2004243542 B2 AU 2004243542B2
- Authority
- AU
- Australia
- Prior art keywords
- inflammatory disease
- syndrome
- conductive fibers
- shielding
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 238000000034 method Methods 0.000 title claims description 58
- 208000027866 inflammatory disease Diseases 0.000 title claims description 38
- 239000004744 fabric Substances 0.000 claims description 29
- 208000002193 Pain Diseases 0.000 claims description 28
- 208000001640 Fibromyalgia Diseases 0.000 claims description 21
- 239000000835 fiber Substances 0.000 claims description 20
- 206010006811 Bursitis Diseases 0.000 claims description 16
- 239000004753 textile Substances 0.000 claims description 14
- 230000005670 electromagnetic radiation Effects 0.000 claims description 12
- 208000024891 symptom Diseases 0.000 claims description 12
- 201000010099 disease Diseases 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 9
- 201000008482 osteoarthritis Diseases 0.000 claims description 8
- 206010043255 Tendonitis Diseases 0.000 claims description 7
- 201000009859 Osteochondrosis Diseases 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 6
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 5
- 201000001947 Reflex Sympathetic Dystrophy Diseases 0.000 claims description 5
- 206010039227 Rotator cuff syndrome Diseases 0.000 claims description 5
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 5
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 4
- 208000005268 Neurogenic Arthropathy Diseases 0.000 claims description 4
- 208000000491 Tendinopathy Diseases 0.000 claims description 4
- 239000000919 ceramic Substances 0.000 claims description 4
- 229910052802 copper Inorganic materials 0.000 claims description 4
- 239000010949 copper Substances 0.000 claims description 4
- 201000006651 patellofemoral pain syndrome Diseases 0.000 claims description 4
- 229910052709 silver Inorganic materials 0.000 claims description 4
- 239000004332 silver Substances 0.000 claims description 4
- 229910001220 stainless steel Inorganic materials 0.000 claims description 4
- 239000010935 stainless steel Substances 0.000 claims description 4
- 208000011580 syndromic disease Diseases 0.000 claims description 4
- 201000004415 tendinitis Diseases 0.000 claims description 4
- 208000013586 Complex regional pain syndrome type 1 Diseases 0.000 claims description 3
- 208000030858 Myofascial Pain Syndromes Diseases 0.000 claims description 3
- 206010029326 Neuropathic arthropathy Diseases 0.000 claims description 3
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 3
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 3
- 208000012322 Raynaud phenomenon Diseases 0.000 claims description 3
- 208000024288 Rotator Cuff injury Diseases 0.000 claims description 3
- 201000006490 Spondylolysis Diseases 0.000 claims description 3
- 208000002240 Tennis Elbow Diseases 0.000 claims description 3
- 206010010121 compartment syndrome Diseases 0.000 claims description 3
- 239000013078 crystal Substances 0.000 claims description 3
- 230000008021 deposition Effects 0.000 claims description 3
- 208000005198 spinal stenosis Diseases 0.000 claims description 3
- 108010085443 Anserine Proteins 0.000 claims description 2
- 208000030016 Avascular necrosis Diseases 0.000 claims description 2
- 206010008334 Cervicobrachial syndrome Diseases 0.000 claims description 2
- 208000001708 Dupuytren contracture Diseases 0.000 claims description 2
- 201000011275 Epicondylitis Diseases 0.000 claims description 2
- 208000020111 Freiberg disease Diseases 0.000 claims description 2
- 201000005569 Gout Diseases 0.000 claims description 2
- 206010020877 Hypertrophic osteoarthropathy Diseases 0.000 claims description 2
- SLRNWACWRVGMKD-UHFFFAOYSA-N L-anserine Natural products CN1C=NC(CC(NC(=O)CCN)C(O)=O)=C1 SLRNWACWRVGMKD-UHFFFAOYSA-N 0.000 claims description 2
- 208000026616 Ollier disease Diseases 0.000 claims description 2
- 208000020971 Osgood-Schlatter disease Diseases 0.000 claims description 2
- 208000010191 Osteitis Deformans Diseases 0.000 claims description 2
- 208000002804 Osteochondritis Diseases 0.000 claims description 2
- 208000006024 Osteochondromatosis Diseases 0.000 claims description 2
- 206010031264 Osteonecrosis Diseases 0.000 claims description 2
- 208000001132 Osteoporosis Diseases 0.000 claims description 2
- 208000027067 Paget disease of bone Diseases 0.000 claims description 2
- 206010034464 Periarthritis Diseases 0.000 claims description 2
- 208000010332 Plantar Fasciitis Diseases 0.000 claims description 2
- 241000210053 Potentilla elegans Species 0.000 claims description 2
- 206010039361 Sacroiliitis Diseases 0.000 claims description 2
- 206010039710 Scleroderma Diseases 0.000 claims description 2
- 206010062164 Seronegative arthritis Diseases 0.000 claims description 2
- 206010048873 Traumatic arthritis Diseases 0.000 claims description 2
- MYYIAHXIVFADCU-QMMMGPOBSA-N anserine Chemical compound CN1C=NC=C1C[C@H](NC(=O)CC[NH3+])C([O-])=O MYYIAHXIVFADCU-QMMMGPOBSA-N 0.000 claims description 2
- 208000016738 bone Paget disease Diseases 0.000 claims description 2
- 208000003295 carpal tunnel syndrome Diseases 0.000 claims description 2
- 208000002849 chondrocalcinosis Diseases 0.000 claims description 2
- 201000007391 chondromalacia patellae Diseases 0.000 claims description 2
- OLSDWRNWUGHKSY-UHFFFAOYSA-J dicalcium;phosphonato phosphate;dihydrate Chemical compound O.O.[Ca+2].[Ca+2].[O-]P([O-])(=O)OP([O-])([O-])=O OLSDWRNWUGHKSY-UHFFFAOYSA-J 0.000 claims description 2
- 201000000863 olecranon bursitis Diseases 0.000 claims description 2
- 201000006292 polyarteritis nodosa Diseases 0.000 claims description 2
- 208000005987 polymyositis Diseases 0.000 claims description 2
- 208000005528 popliteal cyst Diseases 0.000 claims description 2
- 206010043121 Tarsal tunnel syndrome Diseases 0.000 claims 1
- 230000005672 electromagnetic field Effects 0.000 description 11
- 239000003814 drug Substances 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 239000000902 placebo Substances 0.000 description 10
- 229940068196 placebo Drugs 0.000 description 10
- 210000000170 cell membrane Anatomy 0.000 description 7
- 206010061218 Inflammation Diseases 0.000 description 6
- 206010003246 arthritis Diseases 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 230000035699 permeability Effects 0.000 description 5
- 208000000112 Myalgia Diseases 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- 230000008733 trauma Effects 0.000 description 4
- 230000002917 arthritic effect Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000007717 exclusion Effects 0.000 description 3
- 208000015001 muscle soreness Diseases 0.000 description 3
- 229920001778 nylon Polymers 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 206010029216 Nervousness Diseases 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 208000025747 Rheumatic disease Diseases 0.000 description 2
- 230000002146 bilateral effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000004020 conductor Substances 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 238000007427 paired t-test Methods 0.000 description 2
- 229960005489 paracetamol Drugs 0.000 description 2
- 238000000554 physical therapy Methods 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 230000000552 rheumatic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000004575 Infectious Arthritis Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010052904 Musculoskeletal stiffness Diseases 0.000 description 1
- 201000002481 Myositis Diseases 0.000 description 1
- 208000004983 Phantom Limb Diseases 0.000 description 1
- 206010056238 Phantom pain Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 210000003617 erythrocyte membrane Anatomy 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 238000009940 knitting Methods 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 230000003119 painkilling effect Effects 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 201000001223 septic arthritis Diseases 0.000 description 1
- 229910001256 stainless steel alloy Inorganic materials 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 239000004758 synthetic textile Substances 0.000 description 1
- 238000009941 weaving Methods 0.000 description 1
- 239000002759 woven fabric Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Professional, Industrial, Or Sporting Protective Garments (AREA)
Description
WO 2004/105528 PCT/CA2004/000786 METHOD AND ARTICLE FOR TREATMENT OF INFLAMMATORY DISEASE Cross-reference to Related Applications 5 This application is a continuation-in-part of United States Patent Application no. 10/445,007 filed 05/27/2003, which is pending. Technical Field 10 The present invention relates to methods of treating pain arising from inflanmatory diseases in mammals such as humans. More particularly the invention relates to methods of treating pain arising from inflammatory diseases by shielding affected areas from high frequency electromagnetic 15 fields. Background Arthritis and rheumatism are general terms for acute and chronic 20 conditions which are widespread in the population whose common symptoms are pain caused by inflammation. Arthritis is characterized by inflammation of a joint, accompanied by pain and swelling. Rheumatism is a general category of conditions characterized by inflammation and pain in muscles and joints and includes arthritis. Forms of arthritis include 25 osteoarthritis. rheumatoid arthritis, ankylosing spondylitis (AS) and systemic lupus erythematosus (SLE). Rheumatic conditions include infectious arthritis, rheumatoid arthritis, arthritis due to rheumatic fever, arthritis due to trauma or degenerative joint disease, myositis, neurogenic arthropathy, bursitis, fibromyositis and hydroarthrosis. The causes of such 30 disease may be other degenerative diseases, trauma or auto-immune diseases such as SLE. What these diseases, referred to herein as inflammatory diseases, share in common is inflammation, causing pain.
WO 2004/105528 PCT/CA2004/000786 -2 Treatment has typically focussed on pain-killing and anti-inflammatory drugs. Fibromyalgia is a widespread arthritic or rheumatic condition which 5 is characterized by chronic pain in fibrous tissues such as muscles and connective tissues, fatigue, multiple tender points, abnormal sleep patterns, stiffness, headaches, irritable bowels numbness and other symptoms. It is also associated with chronic fatigue syndrome. The cause of fibromyalgia is unknown and there are no known cures. Various medications are used 10 to treat fibromyalgia, as well as hypnosis, but there are no known medications which permanently relieve its symptoms. The inventor of the present invention has previously discovered that pain resulting from exposed or damaged nerve ends, commonly referred to 15 as phantom limb pain, can be relieved or alleviated by shielding the painful area with a cloth woven from a yarn containing threads of a conductive metal. As disclosed in United States Patent No. 4,653,473, the contents of which are incorporated herein by reference, which issued to the inventor on 31 March, 1987, the yarn of the cloth used in this previously 20 discovered method is preferably composed of from 2 to 35% by weight of conductive metal filament, and the balance of natural or synthetic textile fiber such as nylon. The metal may be any conductor, but a stainless steel alloy has been found to be effective. 25 The inventor of the present invention has also discovered that a similar method can be used to relieve muscle pain and soreness and reduce nervousness in horses. This method of treating horse pain and nervousness comprises fashioning a horse blanket of a cloth woven from a yarn containing threads of conductive metal, and placing it on the horse. This 30 method is disclosed in United States Patent no. 4,825,877, the contents of which are incorporated herein by reference, which issued to the inventor C.\NRPotbI\DCCGRS\270669_1 DOC-9/03/2010 -3 of the present invention on 2 May, 1989. The inventor of the present invention has also discovered that a similar method can be used to alleviate delayed onset muscle soreness as disclosed in United States Patent no. 6,146,351 issued 14 November, 2000, the contents of which are incorporated herein by reference. See also Zhang J., Clement D, and Taunton J. 5 "The Efficacy of Farabloc, an Electromagnetic Shield, in Attenuating Delayed-Onset Muscle Soreness" Clin J. Sport Med, 2000 Jan;l0(1):15-21. PMID:106995845 [PubMed indexed for MEDLINE]. Up to now the reason for the efficacy of these methods has not been well 10 understood, but was believed to arise from the shielding of electromagnetic fields. While it was suspected that the same method may be beneficial for other types of pain such as arthritic pain, a theoretical or experimental basis for such an application had not been established. However it has now been discovered that a similar method may be implemented successfully in the treatment of inflammatory diseases generally, including 15 fibromyalgia in humans and other arthritic and rheumatoid diseases by shielding affected areas from high frequency electromagnetic radiation while not shielding the area from low frequency radiation. Summary of Invention 20 According to a first aspect of the invention there is provided a method of treatment of pain in a patient caused by an inflammatory disease comprising shielding the affected areas of the patient from high frequency electromagnetic radiation, while not shielding said affected areas from low frequency electromagnetic radiation, for a period of time sufficient 25 to reduce the symptoms. According to a second aspect of the invention there is provided a method of treatment of pain in a patient caused by an inflammatory disease comprising the steps of: (i) providing an article of clothing configured to substantially cover the affected areas of 30 the patient with a high-frequency electromagnetic radiation-shielding cloth which does not shield low frequency electromagnetic radiation; and (ii) said patient wearing said article of C:\NRPortbI\DCOGRS\2760669_1 DOC-9/03/2010 - 3a clothing whereby said affected areas of said patient are substantially covered by said cloth over a period of time sufficient to reduce said pain. The present invention provides a method of treatment of symptoms of 5 inflammatory diseases in a patient comprising shielding the affected areas of the patient from high frequency electromagnetic radiation for a period of time sufficient to reduce the symptoms while permitting low frequency electromagnetic radiation to reach the affected areas. 10 The invention further provides a method of treatment of symptoms of inflammatory diseases in a patient comprising the steps of: (i) providing WO 2004/105528 PCT/CA2004/000786 -4 an article of clothing configured to substantially cover the affected areas of the patient with a cloth comprising between two and thirty-five percent by weight of a continuous system of electrically conductive fibres; and (ii) the patient wearing the article of clothing whereby the affected areas of the 5 trunk of the body of the patient are substantially covered by the conductive cloth over a period of time sufficient to reduce the symptoms. Brief Description of Drawings 10 In drawings which illustrate embodiments of the invention: FIG. 1 illustrates a hospital gown made from a cloth according to the invention. Description 15 Recently there has been increasing interest in electrobiological effects in humans. The use of low frequency electromagnetic fields to promote bone repair is well established. (See Pilla, "Low-intensity electromagnetic and mechanical modulation of bone growth and repair: are 20 they equivalent?" J Orthrop Asc 2002; 7(3): 420-8). Electroporation, the use of high frequency, high voltage pulsed electrostimulation of cellular tissue to increase the permeability of the cell membrane has become well established and is used to enhance chemotherapy drug delivery (Neumann et al. "Fundamentals of electroporative delivery of drugs and genes" 25 Bioelectrochem Bioenerg 1999 Feb; 48(1): 3-16; Gehl "Electroporation:theory and methods, perspectives for drug delivery, gene therapy and research", Acta Physiol Scand 2003 Apr; 177(4); 437-47). Recent studies suggest low frequency electromagnetic fields reduce permeability of cell membranes ((Bordiushkov et al. "Structural-Functional 30 changes in lymphocytes and erythrocyte membranes after exposure to alternating magnetic field" Vpor Med Khim 2000 Jan-Feb; 46(1):72-80; WO 2004/105528 PCT/CA2004/000786 -5 Heida et al. "Investigating membrane breakdown of neuronal cells exposed to non-unoform electric fields by finite-element modelling and experiments" IEEE Trans Biomed Eng 2002 Oct; 49(10): 1195-203). Recent studies have also suggested that application of electromagnetic fields may be used 5 to treat inflammatory diseases (Nindl et al. "Experiments showing that electromagnetic fields can be used to treat inflammatory diseases" Biomed Sci Instrum 2000; 36: 7-13). The present inventor has discovered that pain from inflammatory diseases is reduced by shielding affected areas from high frequency electromagnetic fields. It is believed that by blocking 10 high frequency EMF, the same effect on cell membranes is achieved as if low frequency EMF is applied, namely reduced permeability of cell membranes which in turn reduces inflammation. For purposes of this application, "high frequency electromagnetic fields" means electromagnetic fields having a frequency greater than about 1 megahertz. "Low frequency 15 electromagnetic fields" means electromagnetic fields having a frequency less than about 1 megahertz. This may be accomplished, for example, by clothing in a cover, gown or other form of apparel or wrapping with a sheet of textile where the textile is made from a radiation shielding textile. 20 A suitable covering material for the practice of the method of the invention which both provides the appropriate electromagnetic shielding and the comfort of a standard non-metallic textile is a fabric sold under the trade-mark FARABLOC. High frequency electromagnetic fields greater than 1 MHz such as radio waves are completely blocked by double layers 25 of the FARABLOC material. However low frequency EMF are not blocked. The yam from which the textile is woven is preferably composed of approximately 13% by weight of stainless steel filaments but may be from 2% to 35% by weight of stainless steel filaments. The balance of the yam is a synthetic nylon fiber such as nylon. The yam has an electrical 30 conductance of approximately 330 ohms per centimeter. The preferred WO 2004/105528 PCT/CA2004/000786 -6 fabric has a warp of 24.5 threads per centimeter and a woof of 24.5 threads per centimeter but fabrics of other characteristics, such as knitted fabrics also will be effective. The weight of the woven fabric is preferably approximately 180 grams per square meter. The preferred binding is L 1/1 5 - that is, one thread up and one thread down. The fabric may be knitted as well as woven. Other conductive materials would also be suitable for the conductive fibers, such as copper, silver or ceramics. Other natural or synthetic non-conductive fibers would also be suitable to comprise the yarn. It would also be suitable to utilize cloth woven or knitted of 10 alternate threads of conductive and textile fibers. At the basis of the present invention is the discovery that shielding areas of the body affected by inflammatory diseases from high frequency electromagnetic radiation while permitting low frequency electromagnetic 15 radiation to reach the affected areas has beneficial results in the alleviation of pain. Specifically with respect to fibromyalgia, according to the method of the invention, the fibromyalgia sufferer wears, for example, a gown as 20 designated by reference numeral 10 in Figure 1. The longer the period during which the gown is worn, the better the results, but preferably the gown is worn at least while the patient is sleeping during the night. The gown 10 need not be constructed entirely of the conductive cloth, but the gown should have a large enough area of the conductive cloth 12 to 25 substantially cover the affected areas of the trunk of the patient's body. While the method preferably uses a gown 10, other forms of apparel such as a shirt and pants or jumpsuit may be used, or a sheet or wrap secured about the patient's body using hook and loop fasteners, for example. 30 WO 2004/105528 PCT/CA2004/000786 -7 Summary of the First Study In a first study carried out on 126 patients hospitalized for 20 days, a double blind placebo controlled study was conducted to assess the 5 efficacy of a FARABLOC gown worn at night compared to a placebo gown in alleviating the symptoms of fibromyalgia. Exclusion criteria included recent trauma, secondary fibromyalgia and inappropriate blood parameters. Inclusion criteria focussed on the classic bilateral nine point tender positions of fibromyalgia, scaled from zero to four. All drugs were 10 stopped but paracetamol was provided on demand. Physiotherapy was consistently provided to all patients. Of the 126 patients who took part in the study, 84 wore placebo gowns and 42 wore FARABLOC gowns. Variables of total tenderness of the 18 fibromyalgia points, overall pain using the visual analogue scale and total drug use were assessed on 15 admission and on discharge after 20 days in hospital. The following are the results of the first study. FARABLOC PLACEBO 20 # of subjects 42 84 Age (years) 49.02 48.08 SEX Female 35 72 Male 7 12 25 The difference in pain and tenderness on admission and discharge was as follows: TOTAL TENDERNESS MEAN +/-SD MEAN +/-SD 30 Admission 48.86+/-3.71 49.40+/-4.02 Discharge 38.21+/-6.17 46.87+/-3.43 WO 2004/105528 PCT/CA2004/000786 -8 Difference 10.64+/-5.69 2.54+/-3.40 TOTAL PA1N Admission 7.41+/-0.49 7.41+/-0.52 5 Discharge 5.39+/-0.99** 6.83+/-0.59 Difference 2.03+/-0.99** 0.59+/-0.71 TOTAL DRUG USE 10.69+/-6.68** 26.12+/-9.37 **P<0.001 - Paired t-test 10 There was a strong positive effect of Farabloc on total tenderness, total pain and drug use in the study of fibromyalgia patients during 20 days of hospitalization. 15 Summary of the Second Study In a second study carried out on 25 patients hospitalized for 21 days, a double blind crossover study was conducted to assess the efficacy of a FARABLOC gown compared to a placebo gown in alleviating the 20 symptoms of fibromyalgia. Exclusion criteria included recent trauma, secondary fibromyalgia and inappropriate blood parameters. Inclusion criteria focussed on the classic bilateral nine point tender positions of fibromyalgia, scaled from zero to four. All drugs were stopped but paracetamol was provided on demand. Physiotherapy was consistently 25 provided to all patients. All patients were provided with new gowns on admission and at midpoint of the 21 day hospital period. This created three distinct groups who switched gowns as described. Variables of total tenderness of the 18 fibromyalgia points, overall pain using the visual analogue scale and total drug use were assessed on admission, midpoint 30 and on discharge. The data was analyzed from the midpoint to the WO 2004/105528 PCT/CA2004/000786 -9 discharge period by assessment of change in three variables. The following are the results of the second study. GOWN ORDER GOWN ORDER GOWN ORDER 5 FARABLOC/PLACEBO PLACEBO/PLACEBO P L A C E B 0 / FARABLOC # subjects 11 7 7 CHANGE IN 10 TENDERNESS -6.5+/-5.559** -0.29+/-2.56 8 . 7 1+/ 4.75** CHANGE IN PAIN -13.27+/-11.40** -4.43+/-5.80 16. 15 0 0
+/
8.3 5** 20 CHANGE IN DRUG USE -18.00+/-5.27** -16.00+/-5.10 -9.29+/ 4.39** **P<0.001 - Paired t-test 25 The study found that the changes in tenderness and pain were significantly non-zero in the negative direction for the group which switched from Farabloc to placebo and positive for the group that switched from placebo to Farabloc. This supports the hypothesis that Farabloc reduces tenderness and pain in fibromyalgia patients. 30 WO 2004/105528 PCT/CA2004/000786 - 10 Based on the recent findings regarding electrobiologic effects, it is believed that the beneficial results of the FARABLOC material arise from reducing inflammation in cells due to both blockage of high frequency EMF to prevent increased permeability of the cell membrane and permitting 5 low frequency EMF to reach the cell membranes to decrease permeability of the cell membranes. Consequently the results of the present method would also be applicable in the same way to reduce pain resulting from other inflammatory diseases, in particular the following specific diseases. While for fibromyalgia the trunk of the patient is shielded with Farabloc, 10 other diseases would involve the shielding of the affected areas. The other inflammatory diseases with respect to which pain is alleviated by this method are Achilles tendinitis, Adhesive capsulitis, Ankylosing spondylitis, Anserine bursitis, Avascular necrosis, Bicipital 15 tendinitis, Bursitis, Calcaneal bursitis, Calcium pyrophosphate dihydrate (CPPD), crystal deposition disease, Carpal tunnel syndrome, Chondrocalcinosis, Chondromalacia patellae, Costosternal syndrome, Degenerative joint disease, Dupuytren's contracture, Epicondylitis, Exercise-induced compartment syndrome, Fibromyalgia, Freiberg's disease, 20 Gout, Hypertrophic osteoarthropathy, Impingement syndrome, Myofascial pain syndrome, Neuropathic arthropathy, Olecranon bursitis, Osgood Schlatter's disease, Osteoarthritis, Osteochondromatosis, Osteoporosis, Paget's disease of bone, Patellofemoral pain syndrome, Plantar fasciitis, Polyarteritis nodosa, Polymyositis, Popliteal cysts, Posterior tibial tendinitis, 25 Prepatellar bursitis, Psoriatic arthritis, Raynaud's phenomenon, Reflex sympathetic dystrophy syndrome, Retrocalcaneal bursitis, Rheumatoid arthritis, Rotator cuff tendinitis, Sacroiliitis, Scheuermann's osteochondritis, Scleroderma, Seronegative arthritis, Shoulder-hand syndrome, Spinal stenosis, Spondylolysis, Systemic lupus erythematosus (SLE), Tarsal tunnel 30 syndrome, Tennis elbow, Traumatic arthritis and Trochanteric bursitis.
C:\NRPortbl\DCCGRS\276669 I )DOC-9/03/2010 - 11 As will be apparent to those skilled in the art in the light of the foregoing disclosure, many alterations and modifications are possible in the practice of this invention without departing from the spirit or scope thereof. For example, while a woven cloth has been specified in the description of the preferred embodiment, it will be apparent to those 5 skilled in the art that a non-woven cloth having a grid of conductive filaments will also operate effectively in the method of the invention while retaining the qualities of a normal fabric. It will also be apparent that many variations in the type of conductive thread or yarn and textile fibers used in the cloth and in the manner of weaving or knitting the cloth are possible in the practice of this invention without departing from the scope thereof. 10 Accordingly, the scope of the invention is to be construed in accordance with the substance defined by the following claims. Throughout this specification and the claims which follow, unless the context requires otherwise, the word "comprise", or variations such as "comprises" or 15 "comprising", will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integers or steps. The reference in this specification to any prior publication (or information derived 20 from it), or to any matter which is known, is not, and should not be taken as an acknowledgment or admission or any form of suggestion that that prior publication (or information derived from it) or known matter forms part of the common general knowledge in the field of endeavour to which this specification relates. 25
Claims (35)
1. A method of treatment of pain in a patient caused by an inflammatory disease comprising shielding the affected areas of the patient from high frequency electromagnetic radiation, while not shielding said affected areas from low frequency electromagnetic radiation, for a period of time sufficient to reduce the symptoms.
2. The method of claim I wherein said high frequency electromagnetic radiation has a frequency greater than about 1 megahertz.
3. The method of claim 2 wherein said low frequency electromagnetic radiation has a frequency less than about 1 megahertz.
4. The method of any one of claims 1 to 3 wherein said shielding is accomplished by covering the affected area of said patient with a radiation-shielding textile for a period of time sufficient to reduce said symptoms.
5. The method of claim 4 wherein said radiation-shielding textile comprises between two and thirty-five percent by weight of a continuous system of electrically conductive fibers and the remainder of non-conductive fibers.
6. The method of claim 5 wherein said radiation-shielding textile is a woven cloth and said electrically conductive fibers are stainless steel fibers.
7. The method of claim 5 wherein said radiation-shielding textile is a woven cloth and said electrically conductive fibers are formed of a material selected from the group copper, silver or ceramic.
8. The method of claim 5 wherein said radiation-shielding textile is a knitted fabric and said electrically conductive fibers are stainless steel fibers. C:\NRPonbl\DCOGRS\2760669_ DOC-9/032O10 - 13
9. The method of claim 5 wherein said radiation-shielding textile is a knitted fabric and said electrically conductive fibers are formed of a material selected from the group copper, silver or ceramic.
10. The method of claim 8 wherein said radiation-shielding textile comprises about thirteen percent by weight of a continuous system of electrically conductive fibers and the remainder of non-conductive fibers.
11. A method of treatment of pain in a patient caused by an inflammatory disease comprising the steps of: (i) providing an article of clothing configured to substantially cover the affected areas of the patient with a high-frequency electromagnetic radiation-shielding cloth which does not shield low frequency electromagnetic radiation; and (ii) said patient wearing said article of clothing whereby said affected areas of said patient are substantially covered by said cloth over a period of time sufficient to reduce said pain.
12. The method of claim 11 wherein radiation-shielding cloth comprises between two and thirty-five percent by weight of a continuous system of electrically conductive fibers and the remainder of non-conductive fibers.
13. The method of claim 12 wherein said electrically conductive fibers are formed of a material selected from the group copper, silver or ceramic.
14. The method of claim 11 wherein said radiation-shielding cloth comprises about thirteen percent by weight of a continuous system of electrically conductive fibers and the remainder of non-conductive fibers.
15. The method of any one of claims 1 to 14 wherein said inflammatory disease is selected from the group Achilles tendinitis, Adhesive capsulitis, Ankylosing spondylitis, Anserine bursitis, Avascular necrosis, Bicipital tendinitis, Bursitis, Calcaneal bursitis, Calcium pyrophosphate dihydrate (CPPD), crystal deposition disease, Carpal tunnel C:\NRPobl\DCCAGRS\2760669_ 1.DOC-9/03/2010 - 14 syndrome, Chondrocalcinosis, Chondromalacia patellae, Costosternal syndrome, Degenerative joint disease, Dupuytren's contracture, Epicondylitis, Exercise-induced compartment syndrome, Fibromyalgia, Freiberg's disease, Gout, Hypertrophic osteoarthropathy, Impingement syndrome, Myofascial pain syndrome, Neuropathic arthropathy, Olecranon bursitis, Osgood-Schlatter's disease, Osteoarthritis, Osteochondromatosis, Osteoporosis, Paget's disease of bone, Patellofemoral pain syndrome, Plantar fasciitis, Polyarteritis nodosa, Polymyositis, Popliteal cysts, Posterior tibial tendinitis, Prepatellar bursitis, Psoriatic arthritis, Raynaud's phenomenon, Reflex sympathetic dystrophy syndrome, Retrocalcaneal bursitis, Rheumatoid arthritis, Rotator cuff tendinitis, Sacroiliitis, Scheuermann's osteochondritis, Scleroderma, Seronegative arthritis, Shoulder-hand syndrome, Spinal stenosis, Spondylolysis, Systemic lupus erythematosus (SLE), Tarsal tunnel syndrome, Tennis elbow, Traumatic arthritis and Trochanteric bursitis.
16. The method of any one of claims I to 14 wherein said inflammatory disease is Achilles tendinitis.
17. The method of any one of claims 1 to 14 wherein said inflammatory disease is Ankylosing spondylitis.
18. The method of any one of claims 1 to 14 wherein said inflammatory disease is Bursitis.
19. The method of any one of claims 1 to 14 wherein said inflammatory disease is crystal deposition disease.
20. The method of any one of claims 1 to 14 wherein said inflammatory disease is Carpal tunnel syndrome.
21. The method of any one of claims 1 to 14 wherein said inflammatory disease is Degenerative joint disease. C\NRPolrbl\DCC'GRS\270669_ 1. DOC-9/03/2010 - 15
22. The method of any one of claims 1 to 14 wherein said inflammatory disease is Exercise-induced compartment syndrome.
23. The method of any one of claims 1 to 14 wherein said inflammatory disease is Fibromyalgia.
24. The method of any one of claims I to 14 wherein said inflammatory disease is Myofascial pain syndrome.
25. The method of any one of claims 1 to 14 wherein said inflammatory disease is Neuropathic arthropathy.
26. The method of any one of claims I to 14 wherein said inflammatory disease is Osteoarthritis.
27. The method of any one of claims I to 14 wherein said inflammatory disease is Psoriatic arthritis.
28. The method of any one of claims I to 14 wherein said inflammatory disease is Raynaud's phenomenon.
29. The method of any one of claims I to 14 wherein said inflammatory disease is Reflex sympathetic dystrophy syndrome.
30. The method of any one of claims 1 to 14 wherein said inflammatory disease is Rheumatoid arthritis.
31. The method of any one of claims I to 14 wherein said inflammatory disease is Rotator cuff tendinitis. C-\NRPorbI\DCCGRS\27606691 DOC-91O3/201O - 16
32. The method of any one of claims 1 to 14 wherein said inflammatory disease is Spinal stenosis.
33. The method of any one of claims I to 14 wherein said inflammatory disease is Spondylolysis.
34. The method of any one of claims I to 14 wherein said inflammatory disease is Systemic lupus erythematosus (SLE).
35. The method of any one of claims 1 to 14 wherein said inflammatory disease is Tennis elbow.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/445,007 US6868854B2 (en) | 2003-05-27 | 2003-05-27 | Method and article for treatment of fibromyalgia |
| US10/445,007 | 2003-05-27 | ||
| US10/682,083 US20050070191A1 (en) | 2003-05-27 | 2003-10-10 | Method and article for treatment of inflammatory disease |
| US10/682,083 | 2003-10-10 | ||
| PCT/CA2004/000786 WO2004105528A2 (en) | 2003-05-27 | 2004-05-26 | Method and article for treatment of inflammatory disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2004243542A1 AU2004243542A1 (en) | 2004-12-09 |
| AU2004243542B2 true AU2004243542B2 (en) | 2010-04-22 |
Family
ID=35589281
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2004243542A Ceased AU2004243542B2 (en) | 2003-05-27 | 2004-05-26 | Method and article for treatment of inflammatory disease |
Country Status (2)
| Country | Link |
|---|---|
| AU (1) | AU2004243542B2 (en) |
| CA (1) | CA2524089A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2994003A1 (en) * | 2013-05-10 | 2016-03-16 | Kirwan, Laurence A | Garment closure apparatus, system&method |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6146351A (en) * | 1998-11-10 | 2000-11-14 | Kempe; Frieder K. | Method of reducing delayed onset muscle soreness |
-
2004
- 2004-05-26 AU AU2004243542A patent/AU2004243542B2/en not_active Ceased
- 2004-05-26 CA CA002524089A patent/CA2524089A1/en not_active Abandoned
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6146351A (en) * | 1998-11-10 | 2000-11-14 | Kempe; Frieder K. | Method of reducing delayed onset muscle soreness |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2524089A1 (en) | 2004-12-09 |
| AU2004243542A1 (en) | 2004-12-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20050070191A1 (en) | Method and article for treatment of inflammatory disease | |
| US4825877A (en) | Method of pain reduction using radiation-shielding textiles | |
| US20170056644A1 (en) | Textile-based product | |
| AU2002329223B2 (en) | Device for treating osteoporosis, hip and spine fractures and fusions with electric fields | |
| US4653473A (en) | Method and article for pain reduction using radiation-shielding textile | |
| US8317736B2 (en) | Compression or support stocking | |
| US9603197B2 (en) | Smart thermal textile for acupuncture therapy | |
| WO1999015101A2 (en) | Multilayer conductive appliance having wound healing and analgesic properties | |
| AU2004243542B2 (en) | Method and article for treatment of inflammatory disease | |
| WO2022103507A1 (en) | Nerve stimulation garment | |
| CA2380701A1 (en) | Sanitary article to be worn in contact with the skin, adapted to provide metallotherapy effects | |
| US20110210274A1 (en) | Method for alleviation of menopausal symptoms | |
| CA3006050C (en) | Pain relieving fabric | |
| ES2283489T3 (en) | SUITABLE FABRIC TO PRODUCE A BARRIER EFFECT AGAINST MAGNETIC AND ELECTROMAGNETIC FIELDS AND / OR METAL THERAPY EFFECTS. | |
| WO2001037286A1 (en) | Protective gear for individuals with implanted electronic devices and others exposed to hazardous electromagnetic radiation | |
| JP4093613B2 (en) | Silk and synthetic fiber blended yarn and silk and synthetic fiber blended fabric and clothing | |
| US20100199409A1 (en) | Stockings | |
| CA2601650A1 (en) | Method for alleviation of menopausal symptoms | |
| AU2007216784A1 (en) | Method for alleviation of menopausal symptoms | |
| Ober | Grounding the human body to earth reduces chronic inflammation and related chronic pain | |
| KR200436103Y1 (en) | Knitted fabric for hoses | |
| KR20120004967U (en) | Elbow joint protection brace | |
| JP3066112U (en) | Electrogenic string or cloth material | |
| KR200178322Y1 (en) | Harmful earth-ray shielding system | |
| CN112137184A (en) | Braided fabric with medical function and manufacturing method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |